Skip to main content
NVDA+0.53%AAPL-0.77%GOOGL-1.39%MSFT-0.91%AMZN-1.63%TSM-1.11%SPCX-2.60%META-0.11%AVGO-1.39%TSLA+0.59%SKHY-1.27%BRK-B+0.07%LLY+0.42%MU+0.14%JPM-1.60%WMT-0.56%AMD+1.99%V-0.14%XOM+2.24%JNJ-0.74%ASMLa-1.02%0700.HK+1.90%MA-0.26%INTC+1.24%ABBV+0.54%1398.HK-2.09%CSCO+0.30%CVX+1.84%BAC-0.77%ORCL-0.69%COST-1.48%KO-1.30%DELL+2.29%CAT-0.28%0005.HK-3.21%HSBA.L-2.33%PG+0.37%UNH-1.66%LRCX-2.59%AP2d-2.07%AMAT-1.46%1816.HK-0.46%3988.HK-2.13%NFLX-2.91%GE-2.46%MS-2.27%0857.HK+0.60%HD-1.69%PM-0.15%0939.HK-2.83%USDJPY+0.98%NZDUSD-0.94%CHFJPY+0.76%USDTHB+0.70%CADJPY+0.68%NZDCHF-0.64%NZDCAD-0.64%AUDUSD-0.60%GBPJPY+0.56%GBPNZD+0.55%EURUSD-0.51%EURJPY+0.45%EURNZD+0.44%GBPTRY+0.41%AUDJPY+0.40%GBPUSD-0.39%PLNJPY+0.36%AUDNZD+0.35%NOKJPY+0.34%GBPHKD+0.32%USDCAD+0.31%USDCHF+0.31%SGDJPY+0.29%GBPMXN-0.28%AUDCHF-0.28%AUDCAD-0.28%USDSEK+0.27%USDTRY+0.25%NZDMXN-0.24%EURCAD-0.23%GBPZAR-0.20%EURSEK+0.19%USDSGD+0.19%EURCHF-0.19%GBPAUD+0.18%USDILS+0.16%NZDSGD-0.16%USDNOK+0.13%USDPLN+0.12%GBPCHF-0.11%USDMXN+0.11%EURSGD+0.11%EURCZK+0.10%EURAUD+0.10%GBPCAD-0.09%EURGBP-0.09%AUDDKK-0.08%USDDKK+0.08%CHFSEK+0.08%EURHKD-0.07%EURZAR-0.06%CHFNOK-0.06%USDCNH+0.06%EURNOK+0.05%NZDJPY+0.04%EURPLN+0.04%EURCNH-0.04%USDCOP-0.04%GBPSGD-0.03%AUDSGD+0.03%AUDNOK-0.03%USDHKD+0.02%CADCHF-0.01%USDZAR+0.01%CHFSGD-0.01%EURDKK0.00%USOIL+3.10%COCOA-2.91%COFFEE-2.02%UKOIL+1.66%W1+1.61%S1+1.26%SUGAR-0.99%XNGUSD+0.90%C1+0.80%HG1+0.70%COTTON-0.38%GAGUSD+0.32%BTCUSD-2.25%ETHUSD-3.73%USDTUSD-0.04%XRPUSD-2.24%SOLUSD-3.23%TRXUSDT-0.44%ZECUSDT-3.79%DOGEUSD-2.33%XMRUSDT-0.23%LINKUSD-2.14%XLMUSD-0.03%BCHUSDT-0.85%UNIUSD-2.21%LTCUSD-2.61%HBARUSDT+0.29%TONUSD+26.79%SUIUSD-2.43%TAOUSDT-3.07%AAVEUSD-2.89%DOTUSDT-1.71%ICPUSDT-7.80%ONDOUSDT-3.43%WLDUSDT-1.82%ARBUSDT+14.16%ATOMUSDT-1.72%JUPUSDT-4.30%INJUSDT-10.53%STXUSDT-3.11%FETUSDT-4.41%PYTHUSDT-3.05%TIAUSDT-5.30%SEIUSDT-2.47%IMXUSDT-1.00%OPUSDT-1.70%GRTUSDT-3.39%POLUSDT+0.96%WIFUSDT-4.27%IOTAUSDT-5.82%AXSUSDT-2.99%FARTCOINUSDT-1.12%EOSUSDT-4.57%DYDXUSDT-5.96%ORDIUSDT-2.08%GALAUSDT-1.47%NOTUSDT-1.28%RONINUSDT-14.59%NVDA+0.53%AAPL-0.77%GOOGL-1.39%MSFT-0.91%AMZN-1.63%TSM-1.11%SPCX-2.60%META-0.11%AVGO-1.39%TSLA+0.59%SKHY-1.27%BRK-B+0.07%LLY+0.42%MU+0.14%JPM-1.60%WMT-0.56%AMD+1.99%V-0.14%XOM+2.24%JNJ-0.74%ASMLa-1.02%0700.HK+1.90%MA-0.26%INTC+1.24%ABBV+0.54%1398.HK-2.09%CSCO+0.30%CVX+1.84%BAC-0.77%ORCL-0.69%COST-1.48%KO-1.30%DELL+2.29%CAT-0.28%0005.HK-3.21%HSBA.L-2.33%PG+0.37%UNH-1.66%LRCX-2.59%AP2d-2.07%AMAT-1.46%1816.HK-0.46%3988.HK-2.13%NFLX-2.91%GE-2.46%MS-2.27%0857.HK+0.60%HD-1.69%PM-0.15%0939.HK-2.83%USDJPY+0.98%NZDUSD-0.94%CHFJPY+0.76%USDTHB+0.70%CADJPY+0.68%NZDCHF-0.64%NZDCAD-0.64%AUDUSD-0.60%GBPJPY+0.56%GBPNZD+0.55%EURUSD-0.51%EURJPY+0.45%EURNZD+0.44%GBPTRY+0.41%AUDJPY+0.40%GBPUSD-0.39%PLNJPY+0.36%AUDNZD+0.35%NOKJPY+0.34%GBPHKD+0.32%USDCAD+0.31%USDCHF+0.31%SGDJPY+0.29%GBPMXN-0.28%AUDCHF-0.28%AUDCAD-0.28%USDSEK+0.27%USDTRY+0.25%NZDMXN-0.24%EURCAD-0.23%GBPZAR-0.20%EURSEK+0.19%USDSGD+0.19%EURCHF-0.19%GBPAUD+0.18%USDILS+0.16%NZDSGD-0.16%USDNOK+0.13%USDPLN+0.12%GBPCHF-0.11%USDMXN+0.11%EURSGD+0.11%EURCZK+0.10%EURAUD+0.10%GBPCAD-0.09%EURGBP-0.09%AUDDKK-0.08%USDDKK+0.08%CHFSEK+0.08%EURHKD-0.07%EURZAR-0.06%CHFNOK-0.06%USDCNH+0.06%EURNOK+0.05%NZDJPY+0.04%EURPLN+0.04%EURCNH-0.04%USDCOP-0.04%GBPSGD-0.03%AUDSGD+0.03%AUDNOK-0.03%USDHKD+0.02%CADCHF-0.01%USDZAR+0.01%CHFSGD-0.01%EURDKK0.00%USOIL+3.10%COCOA-2.91%COFFEE-2.02%UKOIL+1.66%W1+1.61%S1+1.26%SUGAR-0.99%XNGUSD+0.90%C1+0.80%HG1+0.70%COTTON-0.38%GAGUSD+0.32%BTCUSD-2.25%ETHUSD-3.73%USDTUSD-0.04%XRPUSD-2.24%SOLUSD-3.23%TRXUSDT-0.44%ZECUSDT-3.79%DOGEUSD-2.33%XMRUSDT-0.23%LINKUSD-2.14%XLMUSD-0.03%BCHUSDT-0.85%UNIUSD-2.21%LTCUSD-2.61%HBARUSDT+0.29%TONUSD+26.79%SUIUSD-2.43%TAOUSDT-3.07%AAVEUSD-2.89%DOTUSDT-1.71%ICPUSDT-7.80%ONDOUSDT-3.43%WLDUSDT-1.82%ARBUSDT+14.16%ATOMUSDT-1.72%JUPUSDT-4.30%INJUSDT-10.53%STXUSDT-3.11%FETUSDT-4.41%PYTHUSDT-3.05%TIAUSDT-5.30%SEIUSDT-2.47%IMXUSDT-1.00%OPUSDT-1.70%GRTUSDT-3.39%POLUSDT+0.96%WIFUSDT-4.27%IOTAUSDT-5.82%AXSUSDT-2.99%FARTCOINUSDT-1.12%EOSUSDT-4.57%DYDXUSDT-5.96%ORDIUSDT-2.08%GALAUSDT-1.47%NOTUSDT-1.28%RONINUSDT-14.59%
AP

Atea Pharmaceuticals, Inc. (AVIR)

NASDAQ • Healthcare

$5.32
+$0.01 (+0.2%)
Market open

Last close at September 14, 2026 at 20:00 UTC

Open$5.31
Previous Close$5.32
Day Range$5.25 - $5.46
Avg. Volume (3M)234.7K
Market Cap$413.3M
52 Week Range
$2.78$6.45
Next EarningsIn 57 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$165.2M
EPS (TTM)
-$2.08
ROA (TTM)
-71.16%
Current Ratio
8.13

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-16.3%Q1 2026-$0.57
+5.0%Q2 2026-$0.57
+26.1%Q3 2026-$0.41
Next

Nov 11

in 57 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +26.1%

Atea Pharmaceuticals’ preliminary results showed EPS of -$0.41 topping the -$0.56 estimate by $0.15 for the second fiscal quarter of 2026, reported August 12, 2026, alongside a net loss that narrowed year over year. Net income was a loss of about $32.9 million, up ~11% from a loss of roughly $37.2 million a year ago, while operating income came in at a loss of about $35.1 million. On a per-share basis, EPS improved ~7% from -$0.44 a year ago. The company generated negative operating cash flow of about $37.1 million during the quarter. Atea remains focused on advancing its antiviral pipeline, including bemnifosbuvir and ruzasvir programs in hepatitis C. For the next period, consensus calls for EPS of -$0.51 on revenue of $50.4 million.

View full earnings history

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company developing oral antiviral therapeutics for patients with serious viral infections. In qualitative terms, it is a clinical-stage biotech business rather than a commercialized drug maker, with its work centered on advancing liver-focused antiviral candidates through human trials.

Name
Atea Pharmaceuticals, Inc.
CEO
Jean-Pierre Sommadossi
Website
www.ateapharma.com
Industry
Healthcare
Year Founded
2012
Employees
55

Today's Snapshot

AI-generated

AVIR opened slightly lower at 5.30, while its sector was flat.

Trading Volume

Below 10d avg (265.5K)

48K

vs S&P 500 Today

Underperforming Market

-2.76%

Updated: September 15, 2026 at 15:01 UTC

Technical Indicators

3 Buy2 Neutral3 Sell
AVIR presents a mixed technical picture with short-term averages above the market and momentum showing slight weakness, while several longer-term averages remain below price, producing a neutral intermediate stance. Oscillators include oversold readings on Williams %R and a low stochastic that hint at mean-reversion potential, yet the CCI and momentum read negative and ADX indicates only a weak trend. Volatility is moderate and OBV is positive, offering some volume support but not enough to resolve the conflicting signals. Technical takeaway: neutral—mixed short-term weakness and longer-term support produce no clear edge.
All signals
  • EMA (5 indicators)$4.55 - $5.37
    Sell
  • RSI (14)45.08
    Neutral
  • Stochastic %K (14, 3, 3)14.64
    Buy
  • MACD Level (12, 26)0.06
    Neutral

Peers & Related Assets

ALLOAllogene Therapeutics, Inc.
$1.780.0%
ARCTArcturus Therapeutics Holdings Inc.
$15.29+3.8%
ENTAEnanta Pharmaceuticals, Inc.
$13.12+1.2%
VNDAVanda Pharmaceuticals Inc.
$5.15+1.2%
TRDAEntrada Therapeutics, Inc.
$7.05+3.7%
VYGRVoyager Therapeutics, Inc.
$3.190.0%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.